Authors: Akkerhuis, KM Deckers, JW Lincoff, AM Tcheng, JE Boersma, E Anderson, K Balog, C Califf, RM Topol, EJ Simoons, ML

Citation: Km. Akkerhuis et al., Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention, J AM MED A, 286(1), 2001, pp. 78-82

Authors: Cho, L Topol, EJ Balog, C Foody, JM Booth, JE Cabot, C Kleiman, NS Tcheng, JE Califf, R Lincoff, MA

Citation: L. Cho et al., Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender - Pooled analysis from EPIC, EPILOG and EPISTENT trials, J AM COL C, 36(2), 2000, pp. 381-386

Authors: Lincoff, AM Tcheng, JE Califf, RM Kereiakes, DJ Kelly, TA Timmis, GC Kleiman, NS Booth, JE Balog, C Cabot, CF Anderson, KM Weisman, HF Topol, EJ

Citation: Am. Lincoff et al., Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab - One-year outcome in the EPILOG trial, CIRCULATION, 99(15), 1999, pp. 1951-1958